Clinical Trial Update: Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine [Phase 2]

View source ↗

Summary

Phase 2 immunogenicity study update for a recombinant HPV 6/11 bivalent vaccine aimed at condylomata acuminata (genital warts).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Condylomata Acuminata

Drugs mentioned

• Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine (HPV-6/11 bivalent vaccine)

Snippet

Sponsor: Jun Zhang | Conditions: Condylomata Acuminata | Phase 2 | Status: UNKNOWN